Improvement of early renal bone disease with alfacalcidol therapy

November 1995
CMAJ: Canadian Medical Association Journal;11/15/1995, Vol. 153 Issue 10, p1470
Academic Journal
journal article
No abstract available.


Related Articles

  • What is the optimal regimen for vitamin D? Cunningham, John // Kidney International Supplement;Dec1999, Issue 73, pS-59 

    Evaluates the latest vitamin D regimens and metabolites as therapies for patients with renal osteodystrophy. Use of calcitriol and alfacalcidol in patients with renal disease; Increasing prevalence of low turnover of bone disease; Need for proper comparison with existing best therapy.

  • Use of active vitamin D sterols in patients with chronic kidney disease, stages 3 and 4. Coburn, Jack W.; Maung, Hla M. // Kidney International Supplement;Jun2003, Issue 85, p49 

    Use of active vitamin D sterols in patients with chronic kidney disease, stages 3 and 4. This paper reviews randomized controlled trials and other reported data on the use of the active vitamin D sterols, such as calcitriol, alfacalcidol, and doxercalciferol, in the management of secondary...

  • Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study. Tanaka, Yoshiya; Mori, Hiroko; Aoki, Takatoshi; Atsumi, Tatsuya; Kawahito, Yutaka; Nakayama, Hisanori; Tohma, Shigeto; Yamanishi, Yuji; Hasegawa, Hitoshi; Tanimura, Kazuhide; Negoro, Nobuo; Ueki, Yukitaka; Kawakami, Atsushi; Eguchi, Katsumi; Saito, Kazuyoshi; Okada, Yosuke // Journal of Bone & Mineral Metabolism;Nov2016, Vol. 34 Issue 6, p646 

    We conducted a prospective multicenter study to assess early changes in the dynamics of bone metabolism in patients with systemic connective tissue diseases following commencement of high-dose glucocorticoid therapy and the benefits of early treatment with bisphosphonate and vitamin D analogue....

  • Potential of alfacalcidol for reducing increased risk of falls and fractures. Ringe, J. D.; Schacht, E. // Rheumatology International;Aug2009, Vol. 29 Issue 10, p1177 

    There are no general accepted strategies for combined drug treatments in osteoporosis, while in other important chronic diseases combinations of different medications are used as a rule to improve therapeutic results and reduce the risk of adverse events. It is suggested that the success of...

  • Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Hamdy, Neveen A.T.; Kanis, John A. // BMJ: British Medical Journal (International Edition);2/11/95, Vol. 310 Issue 6976, p358 

    Examines the efficacy and safety of alfacalcidol in the prevention of renal bone disease when used earlier in course of renal failure. Double blind, prospective, randomized, placebo controlled study of 176 patients aged 18-81; Quantitative histology of bone.

  • Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol. Ringe, J.; Schacht, E. // Rheumatology International;Dec2007, Vol. 28 Issue 2, p103 

    While in other chronic diseases combined treatment regimens are the rule there is a lack of reported experience or study data on combining different specific drugs to treat osteoporosis. Significant differences in the mode of action (MOA) of the substances to be combined may be important for...

  • Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Ringe, Johann D.; Schacht, Erich // Rheumatology International;Jul2004, Vol. 24 Issue 4, p189 

    Severe vitamin D deficiency was identified only in the first decades of the last century as the most common aetiology of rickets in children and osteomalacia in adults. It was later shown that vitamin D is not, as had been supposed, the biologically active principle for healing bone disease but...

  • Various drugs.  // Reactions Weekly;2/11/2012, Issue 1388, p30 

    The article describes the clinical cases of six women and one man, aged 42-83 years, who had end-stage renal disease, who developed calciphylaxis while under monotherapy or combination therapy with alfacalcidol, calcium acetate, calcium carbonate, ferrous sulfate, iron or warfarin.

  • Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome. Yamamoto, Sunao; Okada, Yosuke; Mori, Hiroko; Hirata, Shintaro; Saito, Kazuyoshi; Inokuchi, Nobuo; Tanaka, Yoshiya // Modern Rheumatology (Springer Science & Business Media B.V.);Mar2013, Vol. 23 Issue 2, p401 

    A 62-year-old woman was diagnosed with severe osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome. She was treated with sodium bicarbonate, risedronate, alfacalcidol, and prednisolone (1 mg/kg). By 24 months, renal tubular acidosis was improved and the bone...

  • Clinical Uses of 1-alpha-hydroxycholecalciferol. Vervloet, Marc // Current Vascular Pharmacology;Mar2014, Vol. 12 Issue 2, p300 

    Alfacalcidol is a widely used vitamin D compound, especially in clinical nephrology because it does not require enzymatic activation by the kidneys. For that reason it has been used for decades to treat abnormalities in bone and mineral balance that arise in chronic kidney disease. In this...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics